Eli Lilly and Company company logo

# RNN 1st Gen Model Eli Lilly and Company Pharmaceutical preparations

Prediction models:
Subscribe >> Deal exit on
March 26, 2018
Deal entry on
March 26, 2018
3.73%Expected margin
69.01% successful of 71 deals
$ 74.76 Last close price
at 23-mar-2018


Model's trade recommendations 2.75% Return for period

0.84% Annual return

$85.72B Market Cap

β 0.28  


Model (following trade recommendations)


Underlying stock

S&P 500

Return for period 2.75%
52wk return 4.28%
52wk Range
Sortino ratio 0.12
Sharpe ratio 0.10
Norm. RMSE 0.40%
Downside risk 8.45%
Volatility 9.55%
  • 2.25 (2.88%) Div (Yield)
  • BUY Analysts consensus recommendation

Eli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. They were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and they remain true to that mission in all their work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Eli Lilly and Company (LLY) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 22, 2015.

Market data for LLY model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 1093M
P/E 18.28
Shares Outstanding 1096M
% Held by Insiders 0.20%
% Held by Institutions 77.62%
EPS (last reported FY) $4.28
EPS (last reported Q) $1.14
EPS, estimated (last reported Q) $1.08
Total revenues $23 B
Net income $-0 B